INTERNATIONAL

LUNG CANCER SUMMIT

Live online & On-Site

26th September 2025 in Lausanne, Switzerland

Our Chairs Invite You To Join

ADD THIS TO YOUR CALENDAR

After the resounding success of the virtual International Lung Cancer Summit (ILCS), we extend a warm invitation to join us for the 6th edition of this engaging hybrid conference. Continuing our tradition of excellence, the ILCS will offer insights into the latest breakthroughs and developments in lung cancer treatment. This conference will harness digital platforms to foster meaningful engagement and networking opportunities for attendees from medical offices, universities, and institutes, allowing them to connect with esteemed medical oncologists and industry professionals at the forefront of lung cancer treatment and research. With distinguished speakers from the USA, France, Spain, Ireland, Italy, Netherlands, Germany, Greece, and Switzerland, the ILCS promises to be an invaluable platform for sharing knowledge and advancing seamless treatment practices.

CHUV-HUG Logo
ISREC
IASLC
ETOP
OncoViews

OUR PROGRAM

26th September 2025

Time Zone: Central European Summer Time

9.30

Welcome by Chairs

Solange Peters & Alfredo Addeo

9.35

TRANSFORMING LUNG CANCER CARE: CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS

MARIUS ILIé (FRANCE)

10.00

Therapeutic Options in Targeting EGFR and ALK

Tom John (Australia)

10.25

OTHER ACTIONABLE GENOMIC ALTERATIONS AND RESISTANCE MUTATIONS – TARGETING: HER2, RET, MET, NTRK

Stephanie Saw (Singapore)

10.50

Open Discussion & Coffee Break

11.15

DEBATE: OSIMERTINIB VS. AMI + LAZER – WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?

  • ARGUING IN FAVOR OF AMIVANTAMAB + LAZERTINIB

    Xiuning Le (USA)

  • ARGUING IN FAVOR OF OSIMERTINIB (+/- CHEMO)

    Thomas Newsom-Davis (UK)

11.50

THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES

Noemi Reguart (Spain)

12.15

Lunch Break

14.15

Tailoring IO in Resectable NSCLC: Personalized Approaches for Improved Outcomes

Jonathan Spicer (Canada)

14.45

THE ROLE OF (CHEMO-)RADIOTHERAPY IN UNRESECTABLE STAGE III NSCLC

Andrea Filippi (Italy)

15.10

Open Discussion & Coffee Break

15.30

LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND

Alessandra Curioni-Fontecedro (Switzerland)

15.50

Reshaping Our Approaches in SCLC: Latest Therapeutic Options and Future Strategies

Rami Manochakian (USA)

16.15

Open Questions, Patient Cases & Guidelines

Panel Discussion With All

LED BY a WORLD-LEADING FACULTY

Marius Ilié

France

Tom John

Australia

Xiuning Le

USA

Noemi Reguart

Spain

Andrea Filippi

Italy

Alessandra Curioni

Switzerland

Stephanie Saw

Singapore

Thomas Newsom-Davis

United Kingdom

Rami Manochakian

USA

MEET US IN PERSON IN LAUSANNE

Get A Glimpse Here

Browse Our 2024 Gallery

How Things Went Onsite

See Some Impressions

ADD THIS TO YOUR CALENDAR